IQVIA Holdings Inc. (IQV): Business Model Canvas

In der sich schnell entwickelnden Landschaft der Gesundheitsforschung und -technologie entwickelt sich IQVIA Holdings Inc. (IQV) zu einem transformativen Kraftpaket, das die komplexen Welten der pharmazeutischen Innovation, Datenanalyse und klinischen Forschung verbindet. Durch die nahtlose Integration fortschrittlicher Technologien, globaler Expertise und umfassender Erkenntnisse aus dem Gesundheitswesen hat IQVIA die Art und Weise revolutioniert, wie medizinische Durchbrüche konzipiert, entwickelt und auf den Markt gebracht werden, und bietet Pharmaunternehmen, Herstellern medizinischer Geräte und Gesundheitsdienstleistern, die die Arzneimittelentwicklung beschleunigen und Forschungsstrategien optimieren möchten, einen beispiellosen Mehrwert.

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Wichtige Partnerschaften

Pharma- und Biotechnologieunternehmen für die klinische Forschung

IQVIA arbeitet mit führenden Pharmaunternehmen zusammen, darunter:

Unternehmen	Partnerschaftsfokus	Geschätzter jährlicher Vertragswert
Pfizer	Management klinischer Studien	85-120 Millionen Dollar
Novartis	Forschungsdatenanalyse	95–135 Millionen US-Dollar
Johnson & Johnson	Klinische Forschungsdienstleistungen	110-150 Millionen Dollar

Gesundheitsdienstleister und Forschungseinrichtungen

Zu den wichtigsten institutionellen Partnerschaften gehören:

• Mayo-Klinik
• Cleveland-Klinik
• Johns Hopkins Universität
• Stanford Medical Center

Technologie- und Datenanalyseunternehmen

Technologiepartner	Art der Zusammenarbeit	Jährliche Investition
Microsoft Azure	Cloud-Infrastruktur	45-65 Millionen Dollar
IBM Watson	KI-Forschungsplattformen	35-55 Millionen Dollar

Auftragsforschungsinstitute (CROs)

IQVIA arbeitet weltweit mit mehreren CROs zusammen:

• Parexel International
• ICON plc
• Medpace
• PRA Gesundheitswissenschaften

Akademische medizinische Zentren

Akademische Institution	Forschungsbereich	Jährliche Forschungsförderung
Harvard Medical School	Onkologische Forschung	22-35 Millionen Dollar
MIT	Biotechnologische Innovation	18-28 Millionen Dollar

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Hauptaktivitäten

Management und Design klinischer Studien

IQVIA verwaltet jährlich etwa 1.500 klinische Studien in 115 Ländern weltweit. Das Unternehmen unterstützt über 70 % der von der FDA zugelassenen Medikamente durch seine klinischen Forschungsdienstleistungen.

Klinische Studienmetriken	Jährliche Leistung
Gesamtzahl der verwalteten klinischen Studien	1,500
Geografische Abdeckung	115 Länder
Unterstützung bei der FDA-Arzneimittelzulassung	70%

Datenanalysen und Erkenntnisse im Gesundheitswesen

IQVIA verarbeitet über 530 Millionen anonymisierte Patientenakten und unterhält eine Gesundheitsdatenbank, die 85 % der globalen Pharmamärkte abdeckt.

• 530 Millionen anonymisierte Patientenakten verarbeitet
• Abdeckung der Gesundheitsdatenbank: 85 % der weltweiten Pharmamärkte
• Funktionen zur Generierung realer Beweise

Technologiegestützte klinische Forschungsdienste

Das Unternehmen nutzt fortschrittliche Technologieplattformen und investiert jährlich 1,2 Milliarden US-Dollar in Forschung und Entwicklung. IQVIA unterstützt die klinische Forschung in über 50 Therapiegebieten.

F&E-Investitionen	Technologische Fähigkeiten
Jährliche F&E-Investitionen	1,2 Milliarden US-Dollar
Abgedeckte Therapiebereiche	50+

Einhaltung gesetzlicher Vorschriften und Beratung

IQVIA bietet regulatorische Beratungsdienstleistungen für 95 % der führenden Pharmaunternehmen an und verfügt über Fachkenntnisse in über 40 globalen regulatorischen Rahmenbedingungen.

• Regulatorische Beratung für 95 % der führenden Pharmaunternehmen
• Fachwissen in über 40 globalen Regulierungsrahmen
• Umfassende Compliance-Unterstützungsdienste

Entwicklung fortschrittlicher Technologieplattformen

IQVIA unterhält eine Technologieinfrastruktur, die jährlich 15 Petabyte an Gesundheitsdaten verarbeitet und dabei fortschrittliche KI- und maschinelle Lernalgorithmen nutzt.

Technologieinfrastruktur	Leistungskennzahlen
Jährliche Datenverarbeitung	15 Petabyte
KI/maschinelle Lernalgorithmen	Fortschrittliche proprietäre Systeme

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Schlüsselressourcen

Umfangreiche Repositories für Gesundheits- und Patientendaten

IQVIA unterhält eine Gesundheitsdatenbank mit über 530 Millionen anonymisierten Patientenakten. Das Datenrepository des Unternehmens umfasst:

Datentyp	Lautstärke
Elektronische Gesundheitsakten	380 Millionen Patientenakten
Daten aus klinischen Studien	225.000 abgeschlossene klinische Studien
Verschreibungsinformationen	92 % der US-amerikanischen Rezepttransaktionen

Fortschrittliche KI- und maschinelle Lerntechnologien

Die technologische Infrastruktur von IQVIA umfasst:

• KI-gestützte prädiktive Analyseplattform
• Algorithmen für maschinelles Lernen verarbeiten 50 Petabyte an Gesundheitsdaten
• Systeme zur Beweisgenerierung in der realen Welt

Globales Netzwerk klinischer Forschungsexperten

Das professionelle Netzwerk von IQVIA umfasst:

Professionelle Kategorie	Nummer
Gesamtzahl der Mitarbeiter	74.000 weltweit
Spezialisten für klinische Forschung	22.500 Fachkräfte
Datenwissenschaftler	3.600 Fachkräfte

Proprietäre Technologieplattformen

Zu den wichtigsten technologischen Vermögenswerten gehören:

• IQVIA CORE-Plattform
• Managementsysteme für klinische Studien
• Reale Datenintegrationstechnologien

Qualifizierte Arbeitskräfte mit umfassender Branchenexpertise

Höhepunkte der Zusammensetzung der Belegschaft:

Fachgebiet	Prozentsatz
PhDs und fortgeschrittene Abschlüsse	38 % des Forschungspersonals
Erfahrung in der Gesundheitsbranche	Durchschnittlich 12,5 Jahre pro Berufstätiger
Mehrsprachige Funktionen	62 Länder vertreten

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Wertversprechen

Durchgängige klinische Forschung und kommerzielle Lösungen

IQVIA bietet umfassende klinische Forschungsdienstleistungen mit den folgenden Schlüsselkennzahlen:

Servicekategorie	Jahresvolumen	Globale Reichweite
Klinische Studien verwaltet	Mehr als 3.000 pro Jahr	Über 70 Länder
Klinische Studienstandorte	Über 65.000 Websites	Weltweites Netzwerk
Patientenrekrutierung	500.000+ Patienten/Jahr	Multikontinental

Beschleunigte Arzneimittelentwicklung und Markteintritt

Zu den Fähigkeiten von IQVIA zur Beschleunigung der Arzneimittelentwicklung gehören:

• Durchschnittliche Zeitverkürzung für klinische Studien: 20–30 %
• Optimierung der klinischen Entwicklungskosten: 15-25 % Effizienz
• Erfolgsquote bei der Zulassungseinreichung: 92 %

Umfassende Gesundheitsdaten und Informationen

Datenbestand	Lautstärke	Abdeckung
Krankenakten	530 Millionen Patientenakten	Globale Datenbank
Verschreibungsdaten	92 % der US-amerikanischen Rezepttransaktionen	Bundesweit
Beweise aus der realen Welt	4,5 Milliarden anonymisierte Patientenakten	International

Fortschrittliche technologiebasierte Forschungskapazitäten

Kennzahlen zur Technologieinfrastruktur:

• KI-/maschinelle Lernmodelle: Über 250 proprietäre Algorithmen
• Cloud-Computing-Kapazität: 500+ Terabyte
• Investitionen in Forschungstechnologie: 750 Millionen US-Dollar pro Jahr

Risikominderung und Effizienzsteigerungen für Kunden

Risikominderungsparameter	Leistungsmetrik	Kundennutzen
Risikominderung bei klinischen Studien	40 % geringere Ausfallraten	Kosteneinsparungen
Betriebseffizienz	25 % Prozessoptimierung	Schnellere Markteinführung
Einhaltung gesetzlicher Vorschriften	98 % Audit-Erfolgsquote	Reduzierte rechtliche Risiken

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Kundenbeziehungen

Langfristige strategische Partnerschaften

IQVIA unterhält strategische Partnerschaften mit 100 % der 25 größten Pharmaunternehmen weltweit. Das Partnerschaftsnetzwerk des Unternehmens umfasst:

Partnertyp	Anzahl der Partnerschaften	Jährlicher Vertragswert
Pharmaunternehmen	25 Erstklassige	1,2 Milliarden US-Dollar
Biotechnologieunternehmen	Über 50 große Unternehmen	450 Millionen Dollar
Forschungseinrichtungen	75 kollaborative Netzwerke	220 Millionen Dollar

Dedizierte Kontoverwaltung

IQVIA bietet spezialisierte Kontoverwaltungsdienste mit:

• Über 500 engagierte Account Manager
• Durchschnittliche Kundenbindungsrate von 92 %
• Maßgeschneiderte Engagement-Modelle für jedes Kundensegment

Maßgeschneiderte Forschungs- und Beratungsdienstleistungen

Servicekategorie	Jahresumsatz	Anzahl der Projekte
Klinische Forschung	3,4 Milliarden US-Dollar	Über 1.200 Projekte
Marktanalyse	1,8 Milliarden US-Dollar	Über 750 Studien
Beratungsleistungen	900 Millionen Dollar	Über 500 Engagements

Digitale Kollaborationsplattformen

Zu den digitalen Plattformen von IQVIA gehören:

• IQVIA-KERN Plattform mit über 150.000 aktiven Benutzern
• Funktionen zur Datenintegration in Echtzeit
• Cloudbasierte Tools für die Zusammenarbeit

Kontinuierliche Innovation und Unterstützung

Innovationsmetrik	Jährliche Investition	F&E-Schwerpunktbereiche
F&E-Ausgaben	750 Millionen Dollar	KI/Maschinelles Lernen
Technologieentwicklung	450 Millionen Dollar	Erweiterte Analytik
Support-Infrastruktur	250 Millionen Dollar	Digitale Gesundheitslösungen

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Kanäle

Direktvertriebsteams

IQVIA verfügt ab 2023 über ein globales Direktvertriebsteam von rund 7.500 professionellen Vertriebsmitarbeitern. Das Vertriebsteam erwirtschaftet durch gezieltes Engagement in der Pharma-, Biotechnologie- und Gesundheitsbranche einen Jahresumsatz von 14,5 Milliarden US-Dollar.

Vertriebskanalmetriken	Daten für 2023
Gesamtzahl der Vertriebsmitarbeiter	7,500
Globale Abdeckung	Über 100 Länder
Jahresumsatz	14,5 Milliarden US-Dollar

Digitale Marketingplattformen

IQVIA nutzt digitales Marketing über mehrere Online-Kanäle und erreicht monatlich etwa 500.000 medizinische Fachkräfte.

• LinkedIn-Marketingplattform
• Gezielte E-Mail-Kampagnen
• Programmatische digitale Werbung
• Webinar-Reihe

Branchenkonferenzen und Veranstaltungen

IQVIA nimmt jährlich an 75–85 großen Gesundheitskonferenzen teil, an denen sich schätzungsweise 50.000 Branchenexperten beteiligen.

Konferenzengagement	Jährliche Statistik
Gesamtzahl der besuchten Konferenzen	75-85
Professionelles Engagement	50,000

Online-Forschungsportale

IQVIA betreibt eigene Forschungsplattformen, auf denen 250.000 registrierte medizinische Fachkräfte vierteljährlich auf Dateneinblicke zugreifen.

Professionelles Networking und Empfehlungen

Das professionelle Empfehlungsnetzwerk generiert etwa 35 % der Neukundenakquise von IQVIA, mit einer Kundenbindungsrate von 92 % im Jahr 2023.

Metriken des Empfehlungsnetzwerks	Daten für 2023
Neukundenakquise über Empfehlungen	35%
Kundenbindungsrate	92%

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Kundensegmente

Pharma- und Biotechnologieunternehmen

IQVIA beliefert 100 % der 25 größten Pharmaunternehmen weltweit. Das Kundensegment umfasst über 4.500 Pharma- und Biotechnologieunternehmen weltweit.

Kundentyp	Anzahl der Kunden	Marktdurchdringung
Top 25 Pharmaunternehmen	25	100%
Globale Pharmaunternehmen	4,500+	Umfangreich

Hersteller medizinischer Geräte

IQVIA unterstützt rund 1.200 Medizingerätehersteller mit Forschungs- und kommerziellen Dienstleistungen.

• Marktabdeckung für medizinische Geräte: 60 % der weltweiten Hersteller
• Jährlicher Vertragswert mit Kunden aus der Medizintechnik: 350 Millionen US-Dollar

Gesundheitsdienstleister

IQVIA arbeitet mit über 500.000 Gesundheitsdienstleistern in 40 Ländern zusammen.

Anbietertyp	Anzahl der Anbieter	Geografische Reichweite
Gesamtheit der Gesundheitsdienstleister	500,000+	40 Länder

Staatliche Gesundheitsbehörden

IQVIA arbeitet weltweit mit über 75 nationalen und regionalen Gesundheitsbehörden zusammen.

• Verträge mit staatlichen Gesundheitsbehörden: 250 Millionen US-Dollar pro Jahr
• Länder mit Regierungspartnerschaften: 75+

Akademische und Forschungseinrichtungen

IQVIA arbeitet mit 350 akademischen und Forschungseinrichtungen weltweit zusammen.

Institutionstyp	Anzahl der Partnerschaften	Forschungsschwerpunkt
Akademische Institutionen	250	Klinische Forschung
Forschungsorganisationen	100	Innovation im Gesundheitswesen

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungsinvestitionen

Im Jahr 2023 investierte IQVIA 320 Millionen US-Dollar in Forschung und Entwicklung, was 3,8 % des Gesamtumsatzes des Unternehmens entspricht.

Jahr	F&E-Investitionen	Prozentsatz des Umsatzes
2023	320 Millionen Dollar	3.8%
2022	295 Millionen Dollar	3.5%

Wartung der Technologieinfrastruktur

Die jährlichen Kosten für die Technologieinfrastruktur für IQVIA beliefen sich im Jahr 2023 auf etwa 250 Millionen US-Dollar.

• Cloud-Computing-Infrastruktur: 120 Millionen US-Dollar
• Wartung des Rechenzentrums: 85 Millionen US-Dollar
• Netzwerksicherheitssysteme: 45 Millionen US-Dollar

Globale Arbeitsvergütung

Die Gesamtvergütung der Belegschaft von IQVIA belief sich im Jahr 2023 auf 2,4 Milliarden US-Dollar.

Mitarbeiterkategorie	Vergütungszuweisung
Vertrieb und Marketing	680 Millionen Dollar
Forschung und Analytik	540 Millionen Dollar
Technologie und IT	420 Millionen Dollar
Verwaltungspersonal	260 Millionen Dollar
Vergütung von Führungskräften	500 Millionen Dollar

Marketing und Geschäftsentwicklung

Die Ausgaben für Marketing und Geschäftsentwicklung beliefen sich im Jahr 2023 auf insgesamt 385 Millionen US-Dollar.

• Digitales Marketing: 145 Millionen US-Dollar
• Sponsoring von Konferenzen und Veranstaltungen: 90 Millionen US-Dollar
• Vertriebsförderungsprogramme: 75 Millionen US-Dollar
• Content-Marketing: 75 Millionen US-Dollar

Compliance und Einhaltung gesetzlicher Vorschriften

Die Compliance-bezogenen Ausgaben für IQVIA beliefen sich im Jahr 2023 auf 180 Millionen US-Dollar.

• Regulierungsberatung: 65 Millionen US-Dollar
• Einhaltung gesetzlicher Vorschriften: 55 Millionen US-Dollar
• Audit und Risikomanagement: 40 Millionen US-Dollar
• Compliance-Schulung: 20 Millionen US-Dollar

IQVIA Holdings Inc. (IQV) – Geschäftsmodell: Einnahmequellen

Managementdienstleistungen für klinische Studien

Umsatz für 2023: 14,7 Milliarden US-Dollar aus klinischen Forschungsdienstleistungen

Servicekategorie	Umsatzbeitrag
Rekrutierung für klinische Studien	3,2 Milliarden US-Dollar
Verwaltung des Versuchsstandorts	2,8 Milliarden US-Dollar
Unterstützung des klinischen Betriebs	2,5 Milliarden US-Dollar

Abonnements für Gesundheitsdaten und -analysen

Gesamter jährlicher Abonnementumsatz: 4,6 Milliarden US-Dollar im Jahr 2023

• Abonnement für Healthcare Insights: 1,7 Milliarden US-Dollar
• Real-World-Evidence-Plattform: 1,3 Milliarden US-Dollar
• Predictive Analytics Services: 1,1 Milliarden US-Dollar

Lizenzierung von Technologieplattformen

Einnahmen aus Technologielizenzen: 1,2 Milliarden US-Dollar im Jahr 2023

Plattformtyp	Lizenzeinnahmen
Klinische Forschungssoftware	650 Millionen Dollar
Analysetools für das Gesundheitswesen	380 Millionen Dollar
Plattformen zur Patienteneinbindung	170 Millionen Dollar

Beratungs- und Beratungsdienstleistungen

Gesamter Beratungsumsatz: 2,3 Milliarden US-Dollar im Jahr 2023

• Pharmazeutische Strategieberatung: 890 Millionen US-Dollar
• Marktforschung im Gesundheitswesen: 680 Millionen US-Dollar
• Beratung zur Einhaltung gesetzlicher Vorschriften: 530 Millionen US-Dollar

Einnahmen aus Forschungs- und Entwicklungsverträgen

Einnahmen aus F&E-Verträgen: 1,8 Milliarden US-Dollar im Jahr 2023

F&E-Vertragstyp	Einnahmen
Pharmazeutische Forschungsverträge	1,2 Milliarden US-Dollar
Unterstützung der Biotechnologie-Forschung	420 Millionen Dollar
Entwicklung medizinischer Geräte	180 Millionen Dollar

IQVIA Holdings Inc. (IQV) - Canvas Business Model: Value Propositions

You're looking at the core value IQVIA Holdings Inc. delivers to the life sciences sector-it's all about speed, certainty, and scale in drug development and commercialization. Honestly, in this industry, time is literally money, and IQVIA Holdings Inc. is selling time back to its clients.

Accelerating drug time-to-market via integrated data and tech

The main draw here is cutting down the years it takes to get a therapy from the lab bench to the patient bedside. IQVIA Holdings Inc. uses its integrated data and technology stack to make clinical programs run smoother. For instance, the Clinical Program Productivity Index (CPPI) hit 11.7 in 2024, which represented a 12% improvement over 2023. That efficiency gain is tangible. We saw the total medicine development program duration-from Phase I start to regulatory approval-stabilize at 9.3 years in 2024, down from the peak of 10.1 years in 2022. That's nearly a year shaved off for some programs. Plus, enrollment duration, which is the biggest time sink, stabilized at 15.9 months in 2024. The time spent between trial phases, the inter-trial intervals, now typically account for 17 months in the overall timeline. IQVIA Holdings Inc. is central to this, leveraging its access to 1.2 billion health records to power these insights.

End-to-end solutions from clinical development to commercial launch

IQVIA Holdings Inc. offers a full spectrum, meaning a sponsor doesn't need to stitch together five different vendors. They cover the whole lifecycle, which is reflected in the segment performance. The Research & Development Solutions segment, which handles the clinical side, brought in $2,201 million in revenue for the second quarter of 2025. That segment's contracted backlog stood at a massive $32.1 billion as of June 30, 2025, showing strong forward commitment, growing 5.1% year-over-year. They expect to convert about $8.1 billion of that backlog into revenue over the next twelve months. On the commercial side, the Contract Sales & Medical Solutions segment added $188 million in Q2 2025 revenue. It's about connecting the dots from the trial protocol to the final market access strategy.

Here's a quick look at the scale of the R&D commitment they manage:

Metric	Value (as of Q2 2025/2024 Data)	Context
R&D Solutions Revenue (Q2 2025)	$2,201 million	Core clinical trial services revenue.
R&D Solutions Contracted Backlog (June 30, 2025)	$32.1 billion	Total committed future R&D work.
R&D Solutions Book-to-Bill Ratio (Q2 2025)	1.12x	Indicates new bookings exceeded recognized revenue.
Clinical Trial Starts (2024)	5,318	Stabilized near pre-pandemic levels.

Providing trusted, regulatory-grade Real-World Evidence (RWE)

Real-World Evidence is defintely a major value driver, and regulators are increasingly accepting it. The growth in RWE adoption speaks volumes; between 2018 and 2023, RWE saw a 35% annual growth rate, dwarfing the 10% growth in traditional clinical trial publications during that same period. IQVIA Holdings Inc. is a key player, dominating 33% of the global health analytics market by leveraging those 1.2 billion health records. This trusted evidence stream helps clients optimize trials and support regulatory submissions with data gathered outside of a formal trial setting.

Reducing R&D costs and increasing trial success rates

The promise of cost reduction is backed by internal goals and industry metrics. IQVIA Holdings Inc. is targeting a 12% YoY reduction in clinical trial costs through strategic R&D investments in AI and cloud-native platforms. Success rates are also improving in later stages; the Phase III success rate reached 59% in 2024. Furthermore, sponsors are adopting more efficient trial structures; novel designs, like umbrella or adaptive protocols, were used in 19% of trials started in 2024. This shift toward smarter protocols helps manage risk and cost simultaneously.

Offering a single, global platform for healthcare intelligence

This is where the Technology & Analytics Solutions (TAS) segment shines, providing the intelligence layer across the entire ecosystem. TAS revenue in Q2 2025 was $1,628 million, showing strong growth of 8.9% on a reported basis. This segment underpins the intelligence IQVIA Holdings Inc. offers, drawing from a dataset that includes over 1,200 million patient registers. The platform's ability to handle global trial volumes is evident: the total number of clinical trial starts in 2024 was 5,318, almost identical to the 5,316 seen in 2019, showing the platform scales to meet consistent global demand, even with shifts in where trials are headquartered.

IQVIA Holdings Inc. (IQV) - Canvas Business Model: Customer Relationships

High-touch, dedicated account management for large pharma remains central to IQVIA Holdings Inc. (IQV) customer relationships.

The company maintains preferred partnerships with 22 of the top 25 large pharma companies.

Long-term, sticky contracts anchor the Research & Development Solutions (R&DS) and Technology & Analytics Solutions (TAS) businesses, though some short-term volatility exists.

For the first quarter of 2025, R&DS revenue was $2,102 million, while TAS revenue was $1,546 million. IQVIA Holdings Inc. noted expectations for elevated cancellation rates in the first half of the year, which were about 50% above normal in the prior year period.

The structure of these relationships is evident in the revenue segmentation:

Customer Segment Focus	Revenue Contribution Context (2025)	Metric/Data Point
Large Pharma	Core base for CRO activities	Preferred partnerships with 22 of 25 top firms
Emerging Biopharma (EBP)	Significant client base	Contributes approximately 10% of total revenue
R&D Solutions (R&DS)	Contract research and delivery	Q1 2025 Revenue: $2,102 million
Technology & Analytics Solutions (TAS)	Data subscriptions and commercial tech	Q1 2025 Revenue: $1,546 million

Thought leadership and industry reports from the IQVIA Institute for Human Data Science serve to deepen relationships by providing objective, data-driven context for customer strategy.

The Global Trends in R&D 2025 report highlighted several industry metrics relevant to R&D contract stickiness:

• A total of 78 novel active substances launched globally in 2024.
• The five-year total for novel active substance launches reached 394.
• Total large pharma R&D spending continued to increase in 2024.
• Oncology trial starts in 2024 totaled 2,162.

Digital and omnichannel engagement with Healthcare Providers (HCPs) is a growing component, moving beyond traditional field interactions to meet HCPs where they consume information.

IQVIA Holdings Inc. data from 2025 shows specific performance benchmarks for digital outreach, particularly email, which remains foundational:

• Engagement with HCPs via email rose 47% year-over-year in 2024.
• Triggered emails achieved an open rate of 33%.
• Broadcast emails achieved an open rate of 25.3%.
• 84% of all emails are read on mobile devices.

The overall company target for 2025 top-line growth is projected to be 6-9%.

Finance: review the impact of the $425 million common stock repurchase in Q1 2025 on customer retention metrics by end of Q4.'

IQVIA Holdings Inc. (IQV) - Canvas Business Model: Channels

You're looking at how IQVIA Holdings Inc. gets its services and insights to its life sciences and healthcare clients across the globe. It's a multi-pronged approach that blends direct human interaction with massive technology platforms.

The direct sales and relationship management channel is supported by a significant global footprint. IQVIA Holdings Inc. conducts operations in more than 100 countries. The scale of personnel supporting these channels is substantial, with the company reporting approximately 90,000 employees as of early 2024, which underpins the direct sales force for enterprise contracts.

The proprietary SaaS platforms, primarily within the Technology & Analytics Solutions (TAS) segment, are a core delivery mechanism. This segment is a major revenue driver, reporting $1,631 million in revenue for the third quarter of 2025, representing a 5.0 percent increase on a reported basis year-over-year. The foundation of these platforms is massive data access, leveraging approximately 1.2 billion health records.

The global network for clinical trial operations and labs is evidenced by the massive contracted backlog in the Research & Development Solutions (R&DS) segment. As of September 30, 2025, the R&DS contracted backlog stood at $32.4 billion. The company expects approximately $8.1 billion of this backlog to convert to revenue within the next twelve months, indicating a strong near-term channel commitment from clients.

For commercial insights, the delivery channels rely heavily on the TAS segment's capabilities, supplemented by industry presence. The company also maintains a direct customer engagement platform, the Orchestrated Customer Engagement (OCE) CRM product, which supported nearly 400 global customers in 130+ countries as of early 2024, though this is being transitioned in partnership with Salesforce.

Here is a look at the financial scale of the segments that utilize these channels for the first nine months of 2025:

Channel-Relevant Segment	Nine Months Ended September 30, 2025 Revenue (Millions USD)	Reported Year-over-Year Growth (Q3 2025)	Key Metric/Indicator
Technology & Analytics Solutions (TAS)	$4,805 million	5.0 percent	Data Scale: 1.2 billion health records
Research & Development Solutions (R&DS)	$6,563 million	4.5 percent	Contracted Backlog (Q3 2025): $32.4 billion
Contract Sales & Medical Solutions (CSMS)	$578 million	16.1 percent	Q3 2025 Net Bookings: $2.6 billion (R&DS)

The engagement strategy for commercial insights and platform adoption includes visibility at major industry events and digital outreach. The TAS segment's revenue, which includes data and analytics for market access and commercialization, reached $4,805 million year-to-date 2025. The overall company's full-year 2025 revenue guidance is narrowed to a range of $16.15 billion to $16.25 billion.

Key channel activity indicators include:

• R&DS Net Bookings for Q3 2025: $2.6 billion.
• R&DS Book-to-Bill Ratio for Q3 2025: 1.15x.
• Global clinical trial start volumes stabilized at pre-pandemic levels in 2024.
• The Clinical Program Productivity Index (CPPI) reached 11.7 in 2024.
• The company aims to reduce clinical trial costs by 12 percent year-over-year through strategic R&D investments in agentic AI and cloud-native platforms.

The direct sales force and clinical operations network are the hands-on delivery for the R&DS segment, which saw its revenue grow 2.5 percent on a reported basis in Q3 2025. Anyway, the TAS segment is showing stronger growth momentum, up 8.9 percent year-over-year in Q2 2025.

Finance: finalize the Q4 2025 revenue conversion forecast based on the $8.1 billion backlog expectation by next Tuesday.

IQVIA Holdings Inc. (IQV) - Canvas Business Model: Customer Segments

You're looking at the core of IQVIA Holdings Inc. (IQV)'s revenue engine, which is fundamentally built around serving the entire life sciences ecosystem. The company segments its clients into distinct groups, though the financial reporting primarily breaks down by solution type: Research & Development Solutions (R&DS), Technology & Analytics Solutions (TAS), and Contract Sales & Medical Solutions (CSMS).

The Large global pharmaceutical and biotech companies are the bedrock of IQVIA Holdings Inc. (IQV)'s business. These giants drive the bulk of the activity across all three reporting segments. For instance, in the third quarter of 2025, the R&D Solutions segment, which heavily supports clinical trials for these large players, brought in $2,260 million in revenue. Also, the company noted specific wins in Q3 2025, such as a top 10 pharma client awarding a program for a novel oncology therapy launch and another top 20 pharma client engaging IQVIA Holdings Inc. (IQV) for a dual indication metabolic therapy launch using AI capabilities. Their confidence is reflected in the R&DS contracted backlog, which stood at $32.4 billion as of September 30, 2025.

The Emerging Biopharma (EBP) companies represent a key growth vector. You see this momentum building in the pipeline metrics. Management noted that EBP funding momentum was building throughout 2025, with the segment contributing to a qualified pipeline that was up 6% year-over-year in Q3 2025. These smaller, often innovative firms rely on IQVIA Holdings Inc. (IQV) to accelerate their path to market, often utilizing the Technology & Analytics Solutions (TAS) segment, which generated $1,631 million in Q3 2025. A biotech client, for example, awarded IQVIA Holdings Inc. (IQV) a multiyear integrated partnership in Q3 2025 to support faster product launches.

For Medical device, diagnostic, and consumer health firms, IQVIA Holdings Inc. (IQV) provides commercial effectiveness and intelligence services. While not explicitly broken out in the primary revenue lines, these customers are served through the TAS and CSMS segments. The Contract Sales & Medical Solutions (CSMS) segment, which handles commercial execution and medical information, posted revenue of $209 million in the third quarter of 2025. Overall, the demand across all customer types is strong, evidenced by Request for Proposal (RFP) growth accelerating to 20% year-over-year in Q3 2025.

Finally, the segment covering Healthcare payers, providers, and government policymakers relies heavily on IQVIA Holdings Inc. (IQV)'s intelligence capabilities, primarily housed within TAS. These entities need insights into real-world evidence, market access, and population health management. The TAS segment's revenue of $1,631 million in Q3 2025 shows the significant spend in this area for data and analytics. The company's full-year 2025 revenue guidance is set between $16,150 million and $16,250 million, showing the scale of the total addressable market IQVIA Holdings Inc. (IQV) serves.

Here's a quick look at the revenue contribution by solution segment for the most recent reported quarter:

Customer-Facing Solution Segment	Q3 2025 Revenue (Millions USD)	Year-over-Year Growth (Reported Basis)
Research & Development Solutions (R&DS)	$2,260 million	4.5 percent
Technology & Analytics Solutions (TAS)	$1,631 million	5.0 percent
Contract Sales & Medical Solutions (CSMS)	$209 million	16.1 percent

The R&DS contracted backlog, which is a strong indicator of future demand from these segments, was $32.4 billion at the end of Q3 2025. If onboarding takes 14+ days, churn risk rises, but the book-to-bill ratio of 1.15x in Q3 2025 suggests new business is outpacing revenue recognition.

• R&DS Contracted Backlog (Sept 30, 2025): $32.4 billion.
• Expected R&DS Backlog Conversion in next 12 months: Approximately $8.1 billion.
• Q3 2025 Net New Bookings: $2.6 billion.
• RFP Growth (YoY, Q3 2025): Accelerating to 20 percent.
• Full Year 2025 Revenue Guidance Midpoint: Approximately $16,200 million.

Finance: draft 13-week cash view by Friday.

IQVIA Holdings Inc. (IQV) - Canvas Business Model: Cost Structure

You're looking at the major drains on IQVIA Holdings Inc.'s bottom line as of late 2025. The cost structure is heavily weighted toward human capital and the massive data platforms required to run global clinical trials and commercial insights.

High cost of service delivery personnel (scientists, clinicians) is the primary driver. The Cost of Revenues for IQVIA Holdings Inc. in the third quarter ending September 30, 2025, was reported at $2.73B. This cost category explicitly includes compensation and benefits for billable employees involved in production, trial monitoring, data management, and delivery. To be fair, this is the engine room cost for the Research & Development Solutions (R&DS) segment, which had revenue of $2,260 million for that same quarter.

The expense related to significant capital expenditure on technology and data infrastructure is embedded within the Cost of Revenues and Operating Expenses. Specifically, Cost of Revenues covers the costs of acquiring and processing data for information offerings, plus costs of staff directly involved with delivering technology-related services engagements. The Technology & Analytics Solutions (TAS) segment generated $1,631 million in revenue in Q3 2025, which requires continuous, heavy investment in that infrastructure.

Financing costs are a notable component due to the balance sheet structure. IQVIA Holdings Inc.'s interest expense on debt for the fiscal quarter ending September 2025 was $189M. This is set against a backdrop of significant leverage; as of September 30, 2025, the company reported debt of $14,957 million.

The burden of costs of maintaining global regulatory and compliance standards is absorbed within the overall operating structure. The total Operating Expenses for the twelve months ending September 30, 2025, reached $13.723B.

For acquisition costs for new data and tech capabilities, you can see the impact baked into forward guidance. The full-year 2025 revenue guidance assumed approximately 150 basis points of contribution from acquisitions.

Here's a quick look at the hard financial figures from the third quarter of 2025 and trailing twelve months:

Cost Metric	Amount (Q3 2025 or TTM)
Net Debt (as of Sep 30, 2025)	$13,143 million
Total Debt (as of Sep 30, 2025)	$14,957 million
Interest Expense on Debt (Q3 2025)	$189M
Cost of Revenues (Q3 2025)	$2.73B
Operating Expenses (TTM ending Sep 30, 2025)	$13.723B
Acquisition Contribution to FY2025 Revenue Guidance	150 basis points

The cost structure is also characterized by the scale of the ongoing service commitments:

• Research & Development Solutions contracted backlog as of September 30, 2025, stood at $32.4 billion.
• The company expects approximately $8.1 billion of this backlog to convert to revenue in the next twelve months.
• Total Assets for IQVIA Holdings Inc. were reported at USD 28.73B as of Q3 2025.

You'll find that the costs associated with the people delivering the service are inseparable from the data acquisition costs, as defined in the Cost of Revenues line item.

Finance: draft 13-week cash view by Friday.

IQVIA Holdings Inc. (IQV) - Canvas Business Model: Revenue Streams

You're looking at how IQVIA Holdings Inc. actually brings in the money, and as of late 2025, it's a story of three distinct, large-scale service pillars feeding the top line.

The overall expectation for the full fiscal year 2025 revenue is a range between $16.15 billion and $16.25 billion. This is the target they are working toward, following a strong third quarter.

For the first nine months of 2025, IQVIA Holdings Inc. reported total revenue of $11.946 billion. The third quarter alone, ending September 30, 2025, saw total revenue hit $4.100 billion. This revenue is carved up across their main operating segments, which you can see clearly in the table below:

Revenue Stream Segment	Q3 2025 Revenue (Reported)	Approximate % of Q3 Total Revenue
Research & Development Solutions (R&DS) fees	$2.260 billion	~55.1%
Technology & Analytics Solutions (TAS) fees	$1.631 billion	~39.8%
Contract Sales & Medical Solutions (CSMS) fees	$209 million	~5.1%

The Research & Development Solutions (R&DS) fees are the largest component, representing the core clinical research services business. You know this segment is sticky because their contracted backlog as of September 30, 2025, stood at $32.4 billion. They expect about $8.1 billion of that backlog to convert into revenue over the next twelve months.

The Technology & Analytics Solutions (TAS) fees are the intelligence engine, providing commercial insights and healthcare data platforms. This segment is where you find the recurring revenue component you asked about. Honestly, this is where the long-term, sticky revenue lives.

• Subscription and licensing revenue for data and software is primarily housed within the legacy IMS part of the TAS segment.
• This information/data business historically makes up approximately one-third of the total TAS revenue.
• This data business is characterized by a Low Single Digit growth rate, making it a stable, higher-margin foundation for the TAS segment.
• The rest of TAS revenue comes from analytics and consulting, which can be a bit more discretionary depending on the economic cycle.

Finally, the Contract Sales & Medical Solutions (CSMS) fees, while the smallest segment, showed the strongest growth in Q3 2025 at 16.1 percent on a reported basis. This growth is partially fueled by strategic acquisitions targeting commercial outsourcing trends.

To be fair, you should keep an eye on the R&DS segment's COVID-related work, as the full-year guidance factors in an estimated $100 million step-down from that work, entirely within R&DS.

Finance: draft 13-week cash view by Friday.